We serve Chemical Name:(1-ethylpropyl)MethylaMine 1HCl CAS:52317-98-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:(1-ethylpropyl)MethylaMine 1HCl
CAS.NO:52317-98-3
Synonyms:N-Methyl-3-pentanamine
Molecular Formula:C6H15N
Molecular Weight:101.19000
HS Code:2921199090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:12.03000
Exact Mass:101.12000
LogP:1.78530
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like N-Methyl-3-pentanamine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,N-Methyl-3-pentanamine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,N-Methyl-3-pentanamine Use and application,N-Methyl-3-pentanamine technical grade,usp/ep/jp grade.
Related News: In the context of the new medicine policy, with the development of China’s R & D strength, the number of innovative drugs approved has been blown out, which further strengthened the demand and speed of industrialization of raw materials in China. (1-ethylpropyl)MethylaMine 1HCl manufacturer Catalent��s clinical supply network includes nine cGMP-certified clinical packaging facilities across North America, Europe and Asia, and more than 50 strategically-located depots around the world, providing local and regional options for clinical storage, distribution, expiry update and relabeling services, and clinical returns management. (1-ethylpropyl)MethylaMine 1HCl supplier For Jefferies, this “has not been demonstrated to convincingly reduce Abeta plaque burden, in our view.” The firm forecasts $3 billion in global sales for gantenerumab, but at a striking 0%, “so probability so no contribution.” (1-ethylpropyl)MethylaMine 1HCl vendor For Jefferies, this “has not been demonstrated to convincingly reduce Abeta plaque burden, in our view.” The firm forecasts $3 billion in global sales for gantenerumab, but at a striking 0%, “so probability so no contribution.” (1-ethylpropyl)MethylaMine 1HCl factory In the context of the new medicine policy, with the development of China’s R & D strength, the number of innovative drugs approved has been blown out, which further strengthened the demand and speed of industrialization of raw materials in China.
